11 March 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Grant of Options under Long Term Incentive Plan
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today confirms that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 8 March 2015, details of which were announced on 15 May 2013, have been met. Consequently, Allergy Therapeutics has today granted certain of its directors low cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP as follows:
Director |
Number of Ordinary Shares over which Options granted |
Total number of Ordinary Shares over which Options granted |
Total remaining number of Ordinary Shares provisionally awarded under LTIPs |
|
|
|
|
Manuel Llobet, Chief Executive Officer |
905,000 |
1,529,024 |
1,690,000 |
Ian Postlethwaite, Finance Director |
452,500 |
928,012 |
845,000 |
The Options have been granted in accordance with the LTIP rules and can be exercisable between 11 March 2016 and 11 March 2026 at an exercise price of 0.1p per Ordinary Share.
For further information please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton
[email protected]
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information please see www.allergytherapeutics.com.
